Interferential Current And Trapezius Myofascial Trigger Points

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05275634
Collaborator
(none)
60
1
4
6
10

Study Details

Study Description

Brief Summary

To investigate the effect of different carrier frequencies of interferential current on pressure pain threshold, neck disability, cervical range of motion and upper trapezius muscle activity when applied on upper trapezius chronic myofascial trigger points: Randomized Controlled Trial

Condition or Disease Intervention/Treatment Phase
  • Other: Stander treatment
  • Device: Interferential current with carrier frequency 2 KHz
  • Device: Interferential current with carrier frequency 4 KHz
  • Device: Interferential current with carrier frequency 8 KHz
  • Device: placebo interferential current
N/A

Detailed Description

Interferential current (IFC) is a medium frequency current derived from the interference of two symmetrical, but asynchronous alternating currents ranged from 1 to 10 KHz. The two main currents resulting in a single interference current with properties uniquely different from the two original currents.The lesser current of the two original currents is termed the carrier frequency and the interference current is called the beat frequency. A specific beat frequency can be obtained from several possible interference currents as long as the difference between the original currents is the same. For electro pain modulation, IFC is commonly used form of electrotherapy. It has the advantage of reducing the skin impedance, deeper penetration into tissues and is perceived as more comfortable.

Myofascial pain syndrome (MPS) is a common form of chronic musculoskeletal pain that widely spread and contributing to a significant financial burden and job- related disability. It represents the most common disorder in patients with nonspecific chronic neck pain.The main characteristics of MPS include the presence of myofascial trigger points (MTrPs) which are defined as hyperirritable nodule in a taut band of skeletal muscle fibers which is palpable and tender during physical examination. Trigger points (TrPs) are usually seen in the upper fiber of trapezius. TrPs can be clinically classified as either active or latent. Active TrPs was defined as: MTrPs that refer pain during activity and during rest without any pressure.

They prevent full muscle lengthening and induce their weakness. Latent TrPs was defined as:

MTrPs that is painful only when palpated. Evidence on the effect of IFC on pain modulation is not confirmed up till now. This might be attributed to multiple factors such as limited number of studies, inappropriate use of the parameters or using single carrier frequency (4 KHz) in majority of studies and the physiological effects of all our modalities are dose dependent. Dose depends on details of parameters including frequency. For IFC, the carrier frequency of the current has been suggested as an important parameter to achieve the most effective hypoalgesic response. However, there remains no evidence to support the selection of one carrier frequency over another. Few studies were conducted to examine the effect of different carrier frequencies by comparing their individual effects. Further researches are needed to prove which carrier frequency is more effective in treatment. Therefore, this study will be conducted to compare the effect of different carrier frequencies of the IFC in the management of upper trapezius chronic TrPs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This trial has four groups; three experimental and one group control.This trial has four groups; three experimental and one group control.
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Different Carrier Frequencies of Interferential Current on Upper Trapezius Myofascial Trigger Points: A Randomized Controlled Trial
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Oct 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Standard treatment and interferential current with carrier frequency 2 KHz

Standard treatment and interferential current with carrier frequency 2 KHz will be received three times a week for four weeks.

Other: Stander treatment
Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Device: Interferential current with carrier frequency 2 KHz
Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Experimental: Standard treatment and interferential current with carrier frequency 4 KHz

Standard treatment and interferential current with carrier frequency 4 KHz will be received three times a week for four weeks.

Other: Stander treatment
Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Device: Interferential current with carrier frequency 4 KHz
Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Experimental: Standard treatment and interferential current with carrier frequency 8 KHz

Standard treatment and interferential current with carrier frequency 8 KHz will be received three times a week for four weeks.

Other: Stander treatment
Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Device: Interferential current with carrier frequency 8 KHz
Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Placebo Comparator: Standard treatment and placebo interferential current

Standard treatment and placebo interferential current will be received three times a week for four weeks.

Other: Stander treatment
Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Device: placebo interferential current
Interferential current intensity will not be raised.

Outcome Measures

Primary Outcome Measures

  1. Change in pressure pain threshold [Immediately after the end of the treatment]

    Pressure pain threshold will be measured by digital pressure algometer

Secondary Outcome Measures

  1. Change in Pressure pain threshold [12 weeks following the end of the treatment]

    Pressure pain threshold will be measured by digital pressure algometer

  2. Change in neck disability [Immediately after the end of the treatment]

    Neck disability will be measured by Arabic neck disability index

  3. Change in neck disability [12 weeks following the end of the treatment]

    Neck disability will be measured by Arabic neck disability index

  4. Change in cervical range of motion [Immediately after the end of the treatment]

    Cervical range of motion will be measured by cervical range of motion device

  5. Change in cervical range of motion [12 weeks following the end of the treatment]

    Cervical range of motion will be measured by cervical range of motion device

  6. Change in upper trapezius muscle activity [Immediately after the end of the treatment]

    Muscle activity will be measured by electromyography in the form of root mean square

  7. Change in upper trapezius muscle activity [12 weeks following the end of the treatment]

    Muscle activity will be measured by electromyography in the form of root mean square

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 29 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ages from18-29 years old with unilateral chronic myofascial trigger points in upper trapezius muscle will be included in this study.

  • Participants have chronic myofascial trigger points if they have pain with pressure, local twitch response, jump sign, limited range of motion and referred pain lies over the lateral aspect of the upper trapezius fibers and superiorly to the ipsilateral occiput.

  • Normal body mass index (BMI) from 18-24.9 Kg/m (BMI = body mass in kg divided by participant height in meters).

Exclusion Criteria:
  • Onset of pain less than 3 months

  • History of whiplash injury

  • History of cervical spine surgery

  • Cervical radiculopathy or myelopathy and cervical disc lesion

  • Cervical spondylolisthesis

  • Having multiple sclerosis, thyroid dysfunction and chronic infection

  • Having rheumatologic condition as poly articular osteoarthritis, rheumatoid arthritis and advanced cervical spine degenerative diseases

  • Skin disease and impaired sensation

  • Phobia of using electrical current

  • Pregnancy, tumor, thrombosis and pacemaker

  • Administration of regular analgesic drugs or any medications that affect skin sensation.

  • Receiving physical therapy intervention during the past three months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of Physical Therapy Cairo University Giza Egypt 12511

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Alaa Samir Elsaid Mohamed, Assistant Lecturer, Cairo University
ClinicalTrials.gov Identifier:
NCT05275634
Other Study ID Numbers:
  • P.T.REC/012/003591
First Posted:
Mar 11, 2022
Last Update Posted:
Mar 11, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alaa Samir Elsaid Mohamed, Assistant Lecturer, Cairo University

Study Results

No Results Posted as of Mar 11, 2022